UBS Global Healthcare Conference - NATERA INC

Explicit Guidance:

• 2029 Revenue Target: Management set an indicative long-term goal of $6 billion in annual revenue by 2029, representing a doubling of the current ~$3 billion run rate.
• 2029 ASP Assumption: A reference ASP of $1,450 is cited for the 2029 model, derived from achieving Medicare reimbursement for additional tumor types and full compliance for existing services, distinct from the current ~$1,290 ASP or $3,000+ contracted rates.
• 2029 OpEx/Margin Context: No specific 2029 EBITDA margin guidance provided; however, management notes that hitting the $6B target does not require the 100% EPS dilution associated with current early cancer detection (ECD) investments, which are currently non-reimbursed.
• OPEX Growth: Explicitly stated OPEX growth of approximately 12% for the upcoming year (2024), driven primarily by R&D spending.
• Cash Flow: Reference to the 2024 goal of achieving quarterly cash flow breakeven was met in the prior year; no new cash flow milestone date set for the immediate future beyond the 2029 horizon.

Business-Segment Outlook:

• Signatera (MRD): Expected to generate >$1 billion in revenue in the current year; currently at single-digit market penetration of a $15–$30 billion TAM.
• Signatera Volume Growth: Projected to sustain compounding growth through repeat testing in the installed base and healthy acquisition of new patients; sequential growth is deemed less relevant than year-on-year volume metrics (e.g., +113,000 units YoY growth).
• Signatera Commercial Scale: Commercial team capped at approximately 300–400 reps due to the 11,000 U.S. oncologist ceiling; further headcount growth will not be linear with revenue, supporting high operating leverage and EBITDA expansion.
• Signatera Reimbursement Strategy: Targeting Medicare reimbursement for the remaining ~33% of tumor mix volumes via new Moldex submissions for additional tumor types, viewing this as the primary driver to close the gap to the $1,450 ASP.
• Early Cancer Detection (ECD):
  • CRC Screening: FIND study enrollment completed ahead of schedule; data readout expected in the back half of 2024.
  • CRC Launch Timeline: FDA submission post-readout (~9-month review) followed by US launch in the back half of 2028 or early 2029.
  • MSED (Multi-Screen Early Detection): Strategy is path-dependent on CRC data; plans to leverage CRC technology/assay learnings for rapid application to MSED product, with no specific launch date yet.
• Geographies: Japan launch anticipated by Q1 2025 (J.P. Morgan conference); pricing expected between now and January 2025. Market expected to double the addressable CRC patient pool when combined with the US, though Japan contribution to 2027 revenue deemed minimal.

Market and Competitive Outlook:

• Market Penetration: MRD is described as "early days" with single-digit penetration; Signatera is viewed as a "liquid CT scan" with a broadening tumor mix similar to SEER data.
• Competitive Positioning: Natera claims a leadership position in reproductive health and is dominating the emerging MRD vertical.
• Pricing Dynamics: ASP is expected to increase from current ~$1,290 toward $1,450 (2029 baseline) and potentially $2,000 eventually as Medicare coverage expands to non-covered tumor types.
• Product Evolution: Transitioning from targeted settings (colorectal/breast) to broader liquid biopsy applications; future growth dependent on ECD trials doubling the addressable market again post-2029.

Macro / Industry Outlook:

• Standard of Care: MRD is rapidly emerging as a standard of care; management notes the industry vertical was non-existent a decade ago but is now commonly mentioned.
• Regulatory: Expectation of FDA approval processes taking ~9 months post-data readout; CMS reimbursement readiness anticipated to align with US product launches (2028–2029).
• Market Size Expansion: ECD initiatives (CRC/MSED) are expected to double the total addressable market (TAM) again, creating a ~$15–$30 billion opportunity for each new screen once reimbursement is secured.

Strategic Initiatives:

• Leadership Transition: Immediate handover from CEO Steve R. (Bhavan) to Solomon Solomon (long-tenured employee since 2011, Science lead) effective immediately; no 6-month transitional overlap due to pre-existing involvement of Solomon in all critical decisions.
• R&D Investment: Significant capital allocation to ECD trials (CRC and MSED), currently consuming ~$100M of the ~$950M R&D budget with zero top-line return; expected to shift from 0% leverage to full leverage upon 2028/2029 launches.
• Commercial Expansion: Continued iteration on commercial structure (territories, incentives, cadence) based on 10+ years of operational "wounds and battle scars"; no massive scaling of the sales force anticipated due to market ceiling.
• International Expansion: Preparation for Japan market entry, leveraging existing Japanese KOL relationships and strong local guidelines for CRC MRD.

Risks and Headwinds to Outlook:

• Reimbursement Delays: Failure to secure Medicare coverage for the remaining ~33% of tumor mix volumes could stall ASP growth to the $1,450 target.
• Clinical Trial Outcomes: FIND study readout timing (back half 2024) and results carry uncertainty; management notes "good data" is expected but not guaranteed.
• Regulatory Timelines: FDA review process (~9 months) and subsequent CMS reimbursement decisions could delay the 2028–2029 launch window.
• Operational Execution: Reliance on "good execution" for volume compounding; risks exist in accelerating growth rates beyond sustainable clips.
• Competitive Landscape: Implicit risk of other players entering the MRD or ECD space, though management emphasizes Natera's "liquid CT scan" evolution and early mover status.

Management Tone on the Future:

• Confidence Level: High confidence in the $6B 2029 target, characterized as "eminently achievable" with "good execution" rather than "heroic" growth rates.
• Strategic Clarity: Emphasis on "no dropped balls" due to the seamless leadership transition; culture described as collaborative with deep continuity.
• Motto: "Under-promise and over-deliver"; the $6B target serves as a "rallying cry" and way station rather than a rigid commitment.
• Culture: Strong focus on employee alignment, treating the team as partners in achieving the goal; management notes deep trust in the "long-tenured" executive bench.

Miscellaneous:

• Transition Details: Outgoing CEO Steve R. remains available for clarification and advice under a lengthy transition agreement; no "sitting in meetings" for 6 months required as Solomon is already deeply embedded.
• Sales Force History: Management clarified that commercial success is not attributable solely to the former CEO but to a deep bench of long-tenured sales leaders and a collaborative culture established over the last decade.
• Financial History Reference: 2022 $100M quarterly cash burn mentioned as a catalyst for the 2024 breakeven target, which was successfully met, setting the precedent for current discipline.